George Rho
Contributor since: 2013
Company: 3Dimensional Research
Latest Articles
Genworth Financial: Attractive Arbitrage Profit Potential
Clovis Looks Vastly Overpriced
Synergy's Prospects Are Better Than Recent Price Action Suggests
A Confusing FDA Decision Has Created A Buying Opportunity In Egalet
Avoid Relypsa
Shorting MannKind May Be Far More Dangerous Than Some Might Suggest
2 Critical Catalysts Coming For Acadia Pharmaceuticals
Resetting Expectations For MannKind Corporation
A (Potentially) Final Look At MannKind
AbbVie Stock Has Been Made Cheap By Exaggerated Patent-Related Concerns
Tough To Believe But MannKind Is Making Progress
The Future Of MannKind
A Drug That Destroys Fat Cells Could Make Kythera's Stock Look Beautiful
The Unwinding Of Convertible Notes Has Positive Implications For MannKind
Volatile Theravance Inc. Offers Attractive Total Returns Potential
A Close-Up Look At The Report That Had MannKind Investors Reeling
An Objective, We Think, Up-To-Date Look At MannKind
Enanta Is The Big Winner In The Hepatitis C War Between AbbVie And Gilead
Very Exciting Days Are In Store For Enanta Stockholders
Puma Is As Expensive As MannKind Is Cheap
The State Of MannKind
Acadia Still Offers Considerable Upside Potential
Earnings Are Surging At Packaging Corporation Of America
MannKind Corporation: Back To The Fundamentals
MannKind: Looking Beyond The Short-Term Disappointment
Sanofi Appears To Be In The Early Stages Of An Earnings Rebound
Another Giant Step Forward For Mankind And MannKind
ConAgra Shares Offer Attractive Total Returns Potential
Pricing MannKind Corporation, The Sequel
Little-Known Enanta Has A Lot Going For It
An Opportunity In The Huge Gigamon Sell-Off
The 27-1 AdCom Votes Have So Many Positive Implications For MannKind